The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The company has solid fundamentals for a short-term investment strategy.
The share is getting closer to its long-term support in weekly data, at USD 166.57, which offers good timing for buyers.
The prospective high growth for the next fiscal years is among the main assets of the company
The company returns high margins, thereby supporting business profitability.
Thanks to a sound financial situation, the firm has significant leeway for investment.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The group usually releases upbeat results with huge surprise rates.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For several months, analysts have been revising their EPS estimates roughly upwards.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The stock is in a well-established, long-term rising trend above the technical support level at 166.57 USD
The company's "enterprise value to sales" ratio is among the highest in the world.
With an expected P/E ratio at 100.59 and 90.67 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Sector Other Medical Equipment, Supplies & Distribution